PubMed HealthSearch

PubMed · 1820130

Early graft function.

Abstract

1. One-year graft survival was 83% for patients with excellent function on the first day compared with 65% for patients with poor kidney function. Patients with excellent function at 1 month had an 88% graft survival rate. 2. Patients with poor function at 1 week had lower graft survival rates than those with good function. Interestingly, those who functioned on the first day and then had poor function at 1 week had lower graft survival than those who had poor function from the first day. 3. Patients who worked full-time before transplantation had 3-5% higher 1-year graft survival compared with those who were working part-time. 4. Patients who had urine production on the first day had a 20% higher graft survival. Similar good outcomes were noted in those who did not require dialysis or have rejection episodes prior to discharge. 5. Three-month to 3-year graft survival was 30% higher for those with SCr less than 1.5 mg/dl compared to those with SCr more than 3.0 mg/dl. Patients with no rejections and no dialysis at the time of discharge had a 10% higher 3-year graft survival if Ccr was more than 90 ml/min than those with Ccr less than 60ml/min at the time of discharge. 6. Transplant patients who produced urine on the first-day posttransplant, did not require dialysis at 1 week, and had no rejection episodes by the time of discharge had the highest 1-year graft survival rates (88.7%), whereas those who had delayed function and suffered from rejection episodes had the worst graft survival (51%).(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E C Lim, P I Terasaki. 1991. Early graft function.. https://pubmed.ncbi.nlm.nih.gov/1820130/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Screening for neuroblastoma in the north of England.

OBJECTIVE: To determine the feasibility of establishing a system of screening for neuroblastoma. DESIGN: Prospective study of mass screening in four clearly defined geographical areas. SETTING: Four health districts of the Northern region of England. SUBJECTS: 20,829 babies aged 6 months, 92% of target population. INTERVENTIONS: Collection of urine on filter paper for analysis of content of homovanillic and vanillylmandelic acid in relation to urinary creatinine concentrations. MAIN OUTCOME MEASURES: Derivation of reference range. Identification of babies with homovanillic or vanillylmandelic acid > 3 SD above the mean (positive cases). Investigation of positive cases for evidence of neuroblastoma. RESULTS: The upper limit of normal (3 SD above the mean) for vanillylmandelic acid was 15 mumol/mmol creatinine and for homovanillic acid 24 mumol/mmol creatinine. Of the 20,829 babies screened, 2537 (12.2%) required a second sample to be taken because the first sample was inadequate. Of these, 527 (2.5%) provided a liquid urine specimen and 10 (0.04%) had positive results for neuroblastoma. Two of them had neuroblastoma (true positives) and eight did not (false positives). A further three children from the cohort were subsequently found to have neuroblastoma; they had raised homovanillic acid or vanillylmandelic acid values, or both, but screened negative at 6 months. CONCLUSIONS: Screening for neuroblastoma is possible in the health care system of the United Kingdom. Evaluation of the efficacy of screening in reducing the mortality from neuroblastoma requires a controlled trial.

Creatinine

More on SI units.

Explore the source record for details and available documents.

Creatinine